Hypersensitivity, Immediate Completed Phase 3 Trials for Abrocitinib (DB14973)

Also known as: Type I Hypersensitivity / Immediate Hypersensitivity / Hypersensitivity type I / Hypersensitivity type I NOS / Immediate hypersensitivity reaction

IndicationStatusPhase
DBCOND0031076 (Hypersensitivity, Immediate)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03720470Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyTreatment